These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8389020)

  • 1. Side-effects of desferrioxamine in dialysis patients.
    Boelaert JR; de Locht M
    Nephrol Dial Transplant; 1993; 8 Suppl 1():43-6. PubMed ID: 8389020
    [No Abstract]   [Full Text] [Related]  

  • 2. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST; Pedersen FB
    Nephrol Dial Transplant; 1989; 4(7):676. PubMed ID: 2510071
    [No Abstract]   [Full Text] [Related]  

  • 3. Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.
    Cases A; Kelly J; Sabater F; Torras A; Griño MC; Lopez-Pedret J; Revert L
    Nephron; 1990; 56(1):19-23. PubMed ID: 2234245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal phycomycosis in a hemodialyzed patient receiving deferoxamine.
    Sombolos K; Kalekou H; Barboutis K; Tzarou V
    Nephron; 1988; 49(2):169-70. PubMed ID: 3380233
    [No Abstract]   [Full Text] [Related]  

  • 5. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
    Orton RB; de Veber LL; Sulh HM
    Can J Ophthalmol; 1985 Jun; 20(4):153-6. PubMed ID: 4052864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis].
    Simon P
    Nephrologie; 1986; 7(5):177-80. PubMed ID: 3822038
    [No Abstract]   [Full Text] [Related]  

  • 7. Hearing loss and desferrioxamine in homozygous beta-thalassemia.
    Albera R; Pia F; Morra B; Lacilla M; Bianco L; Gabutti V; Piga A
    Audiology; 1988; 27(4):207-14. PubMed ID: 3190562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ototoxicity of desferrioxamine in hemodialyzed patients].
    Sabater F; Cases A; Deola MD; López-Pedret J; Traserra J; Revert L
    Acta Otorrinolaringol Esp; 1989; 40(1):13-6. PubMed ID: 2629920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
    Schindléry C
    Med J Aust; 1988 Jun; 148(12):662-3. PubMed ID: 3380052
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pigmentary changes of the retina in dialysis patients treated with deferoxamine].
    Mathys B; Baeck A; Verougstraete C; Verstappen A; D'Haene M; Zanen A
    Bull Soc Belge Ophtalmol; 1988; 229():49-60. PubMed ID: 3273254
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P; Ralston AJ; Day JP
    Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on "Irreversible ocular toxicity from single challenge dose of desferrioxamine" by C. Bene et al.
    Yaqoob M; Prabhu P; Ahmad R
    Clin Nephrol; 1991 Sep; 36(3):155. PubMed ID: 1934674
    [No Abstract]   [Full Text] [Related]  

  • 13. Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
    Barratt PS; Toogood IR
    Med J Aust; 1987 Aug; 147(4):177-9. PubMed ID: 3657630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhinocerebral mucormycosis in haemodialysis patients treated with desferrioxamine: possible role of recent surgery as an additional risk factor.
    Wens R; Devriendt J; Collart F; Dratwa M; Bisschop P; Telerman-Toppet N; Douat N
    Nephrol Dial Transplant; 1991; 6(9):656-8. PubMed ID: 1745390
    [No Abstract]   [Full Text] [Related]  

  • 15. Respective role of haemosiderosis and desferrioxamine therapy in the risk from infection of haemodialysed patients.
    Tielemans C; Lenclud C
    Q J Med; 1988 Jul; 68(255):573-4. PubMed ID: 3252307
    [No Abstract]   [Full Text] [Related]  

  • 16. High risk of retinal damage by desferrioxamine in dialysis patients.
    Albalate M; Velasco L; Ortiz A; Monzú B; Casado S; Caramelo C
    Nephron; 1996; 73(4):726-7. PubMed ID: 8856289
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy.
    Milne FJ; Sharf B; Bell P; Meyers AM
    Clin Nephrol; 1983 Oct; 20(4):202-7. PubMed ID: 6641027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of ototoxicity of aminoglycosides "locked" to prevent hemodialysis catheter-related infections.
    Saxena AK
    Hemodial Int; 2006 Jan; 10(1):94. PubMed ID: 16441834
    [No Abstract]   [Full Text] [Related]  

  • 19. [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
    Gaini RM; Moretti E; Boffa C; Terzoli S; Carnelli V
    Pediatr Med Chir; 1988; 10(5):503-4. PubMed ID: 3241755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucormycosis--a new risk of deferoxamine therapy in dialysis patients with aluminum or iron overload?
    Goodill JJ; Abuelo JG
    N Engl J Med; 1987 Jul; 317(1):54. PubMed ID: 3587314
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.